Treatment or reduction of menopausal symptoms

ABSTRACT

There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isotlavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone daidzein, the isotlavone being optionally administered with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients. Therapeutic uses and compositions/foods are also described, comprising daidzein or formononetin optionally in association with one or more pharmaceutically acceptable adjuvants, carriers, food components and/or excipients.

This invention relates to compositions, therapeutic uses and methods oftreatment or prevention of menopausal symptoms and osteoporosis.

Menopausal symptoms and osteoporosis are significant scourges in thefemale population, generally affecting many women in later life.

Menopausal symptoms are very well known and are described, for example,by Greene, J. G. and Cooke, D. J. (1980) British Journal of PsychiatryVolume 136, 486-491 (incorporated herein by reference). Hot flushes areone of the principal menopausal symptoms which are uncomfortable andirritating. Greene and Cooke have developed a score in order to measuremenopausal symptoms in women. This score is approved by the USDepartment of Health and widely used in the medical community. Theindicators of menopausal symptoms according to Greene and Cooke comprisehot flushes, sweating at night, heart beating quickly or strongly,feelings of tension or nervousness, difficulty in sleeping,excitability, attacks of panic, difficulties in concentrating, feelingsof tiredness or lack of energy, unhappiness or depression, cryingspells, irritability, feelings of dizziness or faintness, pressure ortightness in head or body, parts of the body feeling numb or tingling,dry vagina and/or dry mouth, headaches, muscle and joint pains, loss offeeling in hands or feet, breathing difficulties, and loss of interestin sex.

The peri-menopausal stage of life in women is associated with a fall inblood levels of the three major estrogens—estradiol, estrone andestriol—which occurs naturally in women usually between 45-55 years ofage. The primary or acute menopause symptoms which effect menopausalwomen include hot flushes and night sweats. These are associated withoften dramatically increased blood perfusion of the skin producingdiscomfort and sweating.

The precise mechanism of these symptoms is unknown but generally isthought to represent disturbance to normal homeostatic mechanismscontrolling vasomotor activity and thermoregulation.

The fact that treatment and/or prevention with replacement estrogensusually relieves the symptoms (so-called estrogen replacement therapies)establishes the link between these symptoms and an estrogen deficiency.The menopausal stage of life is associated with a wide range of otheracute symptoms as described above and these symptoms are generallyestrogen-responsive.

Osteoporosis is believed to affect one third to one half of allpost-menopausal women. In the United States it has been reported thatannually 500,000 bone fractures occur as a result of osteoporosis. It isfurther reported that nearly one third of women over 65 will suffer atleast one bone fracture resulting from osteoporotic bone weakening.Increased calcium intake and other approaches are suggested to have someeffect. However, the widespread effects of osteoporosis indicateseffective approaches for prevention/treatment have not yet arisen.

It has previously been thought that reduction in endogenous estrogenlevels which occurs prior to menopause causes or contributes to thesymptoms of menopause, as well as post-menopausal osteoporosis.

Isoflavones, being plant chemicals which occur largely in members ofLeguminosae, display a range of biological functions which havesuggested they may be useful in treating a host of medical conditions.

A small sub-group of isoflavones (comprising daidzein, genistein,biochanin, and formononetin and) is distinguished by their ability tobind to estrogen receptors on animal (including human) cells. This isdue to the close similarity of the steric structure of the diphenolicrings of isoflavones with the steroidal ring structure of estrogens suchas estradiol, estrone and estriol. Although having substantially lowerbinding affinity to the receptor compared to steroidal estrogens,estrogenic isoflavones are weakly estrogenic. This group of fiveisoflavones have the most basic diphenolic structure possible incontrast to the relatively more complex structures of other isoflavonoidcompounds. This simplicity of structure and its close proximity in shapeto the steroidal ring structure of estrogenic hormones is believed togrant these compounds their estrogenicity. This group also exhibits arange of biological functions in animal cells which appear to beindependent of the estrogen receptor and these include anti-oxidant,diuretic, anti-spasmolytic and anti-cancer effects. These interestingfunctions with their potential therapeutic benefits has brought thisparticular group of isoflavones to the attention of medical researchersin recent years.

In the plant, the isoflavones can occur in a variety of forms—(i) in thebasic form, (ii) in a malonyl form, and (iii) in an acetyl form; theisoflavones are biologically active in each of these forms. Thenaturally-occurring state for each of these forms is as a glycoside,being bound to a sugar moiety such as glucose to produce a water-solubleform. In this form, the isoflavone has enhanced stability to degradativefactors such as heat, oxidation and ultraviolet irradiation. Thiswater-soluble form also permits transport of the isoflavone both aroundthe plant and intra-cellularly. At the intra-cellular site ofbiochemical function of the isoflavone, an intra-cellular glucosideenzyme cleaves the sugar moiety, leaving the more biologically active,but water-insoluble, aglucone form.

When ingested in the diet, the isoflavones undergo varying degrees ofmetabolism within the gut, within the gut wall, and within the liverbefore entering the parenteral bloodstream to exert their biologicaleffects. The first metabolic process is the hydrolysis of the glucosidicform to the aglucone form. This occurs as a result both of low pH fromgastric acid and of the action of β-glycosidase enzyme activity withinbowel bacteria.

Some of the aglucone isoflavones are absorbed intact and in passingthrough the gut wall are believed to be glucuronated or sulphonated asper steroidal compounds. The bulk of isoflavones are fermented withincolonic bacteria. One of the fermentation processes is to demethylateisoflavones (eg. formononetin gives daidzeiu and biochanin givesgenistein on demethylation). In another series of fermentation steps,daidzein and genistein are converted to a range of end-productsincluding equol, dehydroequol, O-desmethylangolensin (ODMA),6-hydroxy-ODMA, 2-dehydro-ODMA, dihydrodaidzein, tetra-hydrodaidzein anddihydrogenistein. The liver is capable of further demethylation ofisoflavones such as formononetin and biochanin to the more basicdaidzein and genistein structures. The isoflavones and their metabolitesand derivatives circulate freely within the body and are excretedprimarily in the urine with smaller amounts in the faeces.

The possibility that dietary estrogenic isoflavones may have sometherapeutic benefit in acute menopausal symptoms was suggested by theobservation that Japanese women who typically have much higher dietarylevels of isoflavones (mostly derived from soya) compared to women inWestern countries have a reportedly lower incidence of acute menopausalsyndrome symptoms such as hot flushes. This has led to somewhatspeculative claims of therapeutic benefit of the isoflavones from thegroup daidzein, formononetin, biochanin and genistein in the treatmentand/or prevention of acute menopausal syndrome symptoms (U.S. Pat. No.5,498,631—Gorbach et al).

Gorbach analysed urinary isoflavone excretion in Japanese subjects whoconsumed a traditional Japanese low-fat diet. The presence of estrogenicisoflavones in the urine of the women, men and children studiedsuggested to Gorbach that the isoflavones produced a therapeutic effect.The obvious flaws in this study, namely that in a diet with highisoflavone intake significant urinary out-put of isoflavones would beexpected, and the huge number of biochemically active species in anydiet make it impossible to ascribe biological effects to any particularcomponent or components indicate that Gorbach's claims do not standscrutiny. The fact that a community with a particular health profilehappens to have a high dietary level (and high body levels) of a certainplant component in no way establishes cause and effect. This is onlyachieved through appropriately conducted clinical studies where wellaccepted scientific principles can be applied.

Clinical and other studies done to date in this area are highlyequivocal, with no consistent effect reported. Reported studies haveinvolved the challenge of peri-menopausal women either with wholefoodstuffs (such as soyflour) containing isoflavones or with extracts ofsoya or other legumes, often together with other agents such asvitamins, or isoflavones together with estrogen and/or vitamins andvarious minerals. It is to be noted that soy does not contain theisoflavones formononetin and biochanin. Even when a positive clinicaleffect has been obtained, it has been with a mixture of a plurality ofisoflavones, as well as a wide range of other unidentified dietarycomponents and other biologically active components—it is known forexample that other compounds present in legumes such as flavonoids (eg.quercetin, luteolin, kaempferol and lignans) also are estrogenic and itis also likely that among the other 700 or so isoflavonoids present inthe Leguminosae family there are as yet unidentified isoflavonoids withestrogenic activity.

Gorbach suggests that isoflavanoids bind to estrogen receptors, exertingan estrogenic effect in menopausal women. However, it is acknowledgedgenerally that no direct evidence exists to link the presence ofisoflavones with a therapeutic effect in treatment and/or prevention ofacute menopausal syndrome symptoms. But even if such a link could beinferred from the current epidemiological and clinical studies, which itcan not, the question remains what, if any, therapeutic effect is theresult of a collective effect of the estrogenic isoflavones—daidzein,formononetin, biochanin, gcnistein. All four isoflavones are estrogenic,but they have quite different estrogenic potencies. The relativeestrogenicity of genistein, daidzein, formononetin, biochanin is 1.3,0.09, 0.01, 0.07 respectively (relative to 17β-estradiol 100). Henceformononetin and biochanin have negligible estrogenic activity. On thisbasis, and given the relative proportions of daidzein and genistein inthe blood of Japanese maintaining a typical Japanese diet, it might beinferred that genistein potentially is the most potent . isoflavone asfar as acute menopause syndrome symptoms are concerned.

Estrogenic isoflavones have also been identified as possible therapeuticcompounds in the treatment and/or prevention of osteoporosis. Asianpopulations consuming large amounts of phytoestrogen-rich soybeans andvegetables appear to be protected to a greater extent than westernpopulations from the problems associated with osteoporosis. Theseobservations are by no means clear, and arc contradicted in a number ofstudies.

Fujita and Fukase (Proc. Soc. Exp. Biol. Med. 200(2) 149-5, 1992)indicates that in osteoporosis analysis between Japanese and USpopulations diet is not of particular significance, with bone mass beingvery similar in both populations. Instead they suggest the outcomes ofosteoporosis are more likely associated with lifestyle affecting muscledevelopment and motor control. Arjanandi et al (American Institute ofNutrition, p161-167, 1995) indicates that any protective effects of soyon bone is associated with soy protein. Hunt a al (Am. J. Clin. Nutr., p517-523, 1989) indicate that there is no appreciable difference in bonedensity between elderly menopausal omnivores, and elderly menopausalvegetarians whose diet included isoflavone rich plant materials.

Published European Patent Application No. 0135172 (Takeda, published 27May 1985) discloses methods for the treatment of osteoporosis byadministration of 7,4-dihydroxy isoflavone (daidzein) relying on itsestrogenic activity. This finding is inconsistent with the biologicalstudies reported above. Moreover, Tobe et at (Biosci. Biotech. Biochem.61(2) 370-371, 1997) show that daidzein stimulates bone resorption, thatis bone breakdown, and would be contra-indicated for treatingosteoporosis, as it would worsen an existing condition., and possiblypre-dispose a non affected person to osteoporosis.

Against the foregoing background, the present invention is predicatedupon our surprising finding that, within the framework of what wasconjectured regarding the treatment/prevention of menopausal symptomsand osteoporosis, formononetin may be used to treat both menopausalsymptoms and osteoporosis, and daidzein may be used in the treatment ofmenopausal symptoms. Our findings indicate that formononetin haspronounced clinical activity in the treatment and/or prevention ofmenopausal symptoms and in the treatment and/or prevention ofosteoporosis as does daidzein in the treatment/prevention of menopausalsymptoms. This is highly unexpected given the negligible estrogeniceffect of formononetin, the bone resorption activity of daidzein and theestablished view that formononetin was very rapidly metabolised todaidzein in the gut.

SUMMARY OF THE INVENTION

There is provided in a first aspect of this invention a method for thetreatment or prevention of menopausal symptoms or osteoporosis whereinthere is administered to a subject in need of such treatment atherapeutically effective amount of the isoflavone formononetin, or amethod for the treatment or prevention of menopausal symptoms whereinthere is administered to a subject in need of such treatment atherapeutically effective amount of the isoflavone daidzein, theisoflavone being optionally administered with one or morepharmaceutically acceptable adjuvants, carriers and/or excipients.

In another aspect of the invention there is provided a pharmaceuticalcomposition for the treatment or prevention of menopausal symptoms orosteoporosis wherein the said composition comprises the isoflavoneformononetin or a pharmaceutical composition for the treatment orprevention of menopause wherein said composition comprises theisoflavone daidzein together with one or more pharmaceuticallyacceptable adjuvants, carriers and/or excipients.

In another aspect of the invention there is provided use of theisoflavone formononetin in the treatment or prevention of menopausalsymptoms or osteoporosis, or use of the isoflavone daidzein in thetreatment or prevention of menopausal symptoms, the isoflavone beingoptionally administered with one or more pharmaceutically acceptableadjuvants, carriers, and/or excipients.

In a further aspect of the invention there is provided an agent for thetreatment or prevention of menopausal symptoms or osteoporosis, or anagent for the treatment or prevention of menopausal symptoms whichcomprises daidzein optionally in association with one or morepharmaceutically acceptable adjuvants, carriers and/or excipients.

DETAILED DESCRIPTION

Throughout this specification and the appended claims, unless thecontext requires otherwise, the word “comprise”, or variations such as“comprises” or “comprising” or “include” or “including”, will beunderstood to imply the inclusion of a stated element or integer orgroup of elements or integers but not the exclusion of any other elementor integer or group of elements or integers.

The present invention provides in a first aspect a method for thetreatment or prevention of menopausal symptoms or osteoporosis whereinthere is administered to a subject in need of such treatment atherapeutically effective amount of the isoflavone formononetin, or amethod for the treatment or prevention of menopausal symptoms whereinthere is administered to a subject in need of such treatment atherapeutically effective amount of the isoflavone daidzein, theisoflavone being optionally administered with one or morepharmaceutically acceptable adjuvants, carriers and/or excipients.

It is believed that the invention described represents a substantialbreakthrough in the field of treatment and/or prevention of menopausalsymptoms and osteoporosis. The administration to subjects of plantextracts containing a range of isoflavones may be unpleasant in thesense that the extract may not be particularly palatable, and/or maycontain a host of ill-defined compounds which may affect disadvantageousbiological activity. Wilcox et al (British Medical Journal (1990) 301:905) have reported increases in vaginal cell proliferation amongstpost-menopausal women consuming soybean phytoestrogens for six weeks. inaddition Markiewicz et at (J. Steroid Biochem. (1993) 45: 399) haveshown experimentally that the soy isoflavone genistein exhibited anestrogen effect on endometrial cancer cells, that is, potentiated cancercell growth in this cell type. Such reports raise questions about thesafety of comparatively high doses of genistein. The present inventionprovides the treatment or prevention of menopausal symptoms andosteoporosis without any side effects caused by uncharacterisedbiologically active plant materials (such as coumesterols), or otherdisadvantageous effects.

The menopausal symptoms which may be treated according to the method ofthis invention are those described by Greene, J. G. and Cooke, D. J.(1980) British Journal of Psychiatry Volume 136, 486-491. Preferably themenopausal symptoms treated or prevented according to the presentinvention are hot sweats and night time sweats, more particularly hotsweats. Having said this, the method of the invention is applicable tothe treatment and/or prevention of other symptoms of menopause aspreviously described. The isoflavone formononetin is of the formula (I):

Although it was previously thought that formononetin was almostimmediately metabolised (demethylated) to daidzein upon administrationto a subject, the present inventors have found that formononetinpersists in the blood stream for a considerable time (having a half lifeof generally about 20 hours).

The isoflavone daidzein is of the formula (II):

Formononetin or daidzein are preferably administered to a subjectsubstantially unaccompanied by other isoflavones. By this is meant thatany composition or preparations may contain minor amounts of otherisoflavones, in the order of 10% (w/w) or less. Preferably theformononetin or daidzein represents at least 90% of isoflavone content,more preferably 95%, even more preferably 98% or more. Genistein, ifpresent, is in amounts of about 5% or less, more preferably less than 1%(w/w) with regard to isoflavone content. It is recognised by regulatoryagencies that an isoflavone content in the order of 95% of totalisoflavones represents effective purity.

In the treatment of menopausal symptoms formononetin may be administeredin combination with daidzein, for example from a ratio of 1:10 to 10:1.

Daidzein metabolites may be used in place of daidzein in the variousembodiments of this invention, These metabolites include equol,o-desmethylangotensin (ODMA), dehydroequol, 2-dehydro-ODMA,6-hydroxy-ODMA, dihydrodaidzein and tetra-hydrodaidzein (whichcollectively may be referred to hereinafter as daidzein metabolites).Accordingly, in a further aspect this invention extends to a method forthe treatment or prevention of menopausal symptoms or osteoporosiswherein there is administered, to a subject in need of such treatmentand/or prevention, formononetin or a daidzein metabolite, optionallyadministered with one or more pharmaceutically acceptable adjuvants,carriers and/or excipients. The formononetin or daidzein metabolites maybe administered in a form substantially unaccompanied by otherisoflavones.

Daidzein and/or formononetin compositions or preparations areadministered in an amount, and under a dosage regime which gives reliefto menopausal symptoms or osteoporosis. With regard to menopausalsymptoms this can be readily determined by the subject who is beingtreated, or by their physician. Generally, it is found that preventionor therapy of menopausal symptoms and osteoporosis results from dailyadministration of formononetin such as from one to six times in a 24hour period, as does the treatment or prevention of menopausal symptomswith daidzein, so as to give a daily dose of the isoflavone in an amountfrom about 5 mg to about 400 mg per day (this dosage range may bereferred to as the “effective amount”).

Formononetin and daidzein may be prepared by synthesising the compoundsby conventional chemical synthetic techniques as are well known in theart, or by purification from extracts of plants of the genusLeguminosae, particularly from soy (such as from soy flour, soyhypocotyls) and clover (such as red clover, and subterranean clover)such as to form a formononetin or daidzein composition or preparation.

Compositions/preparations administered to subjects for the treatingand/or prevention of, or for reducing the predispositon to, menopausalsymptoms or osteoporosis may comprise in addition to the specificisoflavones previously mentioned formononetin optionally administeredwith one or more pharmaceutically acceptable adjuvants, carriers and/orexcipients, so as to form a composition or preparation. Pharmaceuticallyacceptable adjuvants, carriers and/or excipients, and the like, are wellknown in the art, for example as described in the Handbook ofPharmaceutical Excipients, second edition, American PharmaceuticalAssociation, 1994 (incorporated herein by reference). Daidzein orformononetin may be administered in the form of tablets, capsules,powders for reconstitution, syrups, foods (such as food bars, biscuits,snack foods and other standard food forms well known in the art) or indrink formulations. Drinks may contain flavouring, buffers and the like.

In the method of this invention calcium may be co-administered (that isbefore at the same than or after the isoflavones previously mentioned),for example as a separate tablet, or as part of a suitable dosage form.

In a further aspect of this invention there is provided a pharmaceuticalcomposition for the treatment or prevention of menopausal symptoms orosteoporosis wherein the said composition comprises the isoflavoneformononetin or a pharmaceutical composition for the treatment orprevention of menopause wherein said composition comprises theisoflavone daidzein, together with one or more pharmaceuticallyacceptable adjuvants, carriers and/or excipients. As mentioned above,pharmaceutically acceptable adjuvants, carriers and/or excipients arewell known in the art. Examples include compositions according to thepresent invention may include one or more pharmaceutically acceptablecarriers. The carriers are selected so as to be acceptable in the senseof being ingredients in the composition and must not be deleterious tothe patient. The carriers may be solid or a liquid, or both, and may beformulated with the extract as a unit-dose, for example a tablet, whichmay contain from 0.5% to 59% by weight of the active compound or up to100% by weight to the active compound. Compositions may be prepared byany of the well known techniques of pharmacy, for example admixing thecomponents, optionally including excipients, diluents (for examplewater) and auxiliaries as are well known in the pharmaceutical field.

The compositions of the invention include those suitable for oral,rectal, optical, buccal (for example sublingual), parental (for examplesubcutaneous, intramuscular, intradermal and intravenous) andtransdermal administration. The most suitable route in any given casewill depend on the nature and severity of the condition being treatedand the state of the patient.

Compositions suitable for oral administration may be presented indiscrete units, such as capsules, cachets, lozenges, or tablets, eachcontaining a predetermined amount of the extract; as a powder orgranules; as a solution or a suspension in an aqueous or non-aqueousliquid; or as an oil-in-water or water-in-oil emulsion. Suchcompositions may be prepared by any suitable method of pharmacy whichincludes the step of bringing into association the active isoflavone andone or more suitable carriers (which may contain one or more accessoryingredients as noted above). In general the compositions of theinvention are prepared by uniformly and intimately admixing theisoflavone with a liquid or finely divided solid carrier, or both, andthen, if necessary, shaping the resulting mixture. For example, a tabletmay be prepared by comprising or moulding a powder or granulescontaining the extract, optionally with one or more accessoryingredients. Compressed tables may be prepared by compressing in asuitable machine, the extracts in the form of a powder or granulesoptionally mixed with a binder, lubricant, inert diluents, and/orsurface active/dispersing agent(s). Moulded tablets may be made bymoulding, in a suitable machine, the powdered compound moistened with aninert liquid binder.

Suitable carriers may be fillers, such as sugars, for example lactose,saccharose, mannitol or sorbitol, cellulose preparations and/or calciumphosphates, for example tricalcium phosphate or calcium hydrogenphosphate, and also binders, such as starch pastes using, for example,corn, wheat, rice or potato starch, gelatin, tragacanth, methylceulloseand/or polyvinylpyrrolidone, and, if desired, disintegrators, such asthe above-mentioned starches, also carboxymethyl starch, cross linkedpolyvinyl pyrrolidone, agar or alginic acid or a salt thereat, such assodium alginate. Excipients may be flow conditioners and lubricants, forexample silicic acid, talc, stearic acid or salts thereof, such asmagnesium or calcium stearate, and/or polyethylene glycol. Dragée coresare provided with suitable, optionally enteric, coatings, there beingused, inter alia, concentrated sugar solutions which may comprise gumarabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titaniumdioxide, or coating solutions in suitable organic solvents or solventmixtures, or, for the preparation of enteric coatings, solutions ofsuitable cellulose preparations, such as acetylcellulose phthalate orhydroxypropylmethylcellulose phthalate. Dyes or pigments may be added tothe tablets or dragée coatings, for example for identification purposesor to indicate different doses of active ingredients.

Other orally administrable pharmaceutical compositions are dry-filledcapsules made, for example, of gelatin, and soft, sealed capsules madeof gelatin and a plasticiser, such as glycerol or sorbitol. Thedry-filled capsules may comprise the extracts hi the form of granules,for example in admixture with fillers, such as lactose, binders, such asstarches, and/or glicants, such as talc or magnesium stearate, and,where appropriate, stabilisers. In soft capsules, the extract ispreferably dissolved or suspended in suitable liquids, such as fattyoils, paraffin oil or liquid polyethylene glycols, to which stabilisersmay also be added.

Formulations suitable for buccal (sublingual) administration includelozenges comprising the extracts in a flavoured base, usually sucroseand acacia or tragacanth; and pastilles comprising the compound in aninert base such as gelatin and glycerin or sucrose and acacia.

Formulations suitable for rectal administration are preferably presentedas unit dose suppositories. These may be prepared by admixing theisoflavones with one or more conventional solid carriers, for examplecocoa butter, and then shaping the resulting mixture.

Compositions may include calcium or other active agents suggested toprovide some amelioration of osteoporosis or symptoms of menopause.

Pharmaceutical compositions generally comprise from about 5 mg to about400 mg of the isoflavone/s and may be administered ono or more times perday.

In a further aspect of this invention there is provided use of theisoflavone formononetin in the treatment or prevention of menopausalsymptoms or osteoporosis, or use of the isoflavone daidzein in thetreatment or prevention of menopausal symptoms, the isoflavone beingoptionally administered with one or more pharmaceutically acceptableadjuvants, carriers, and/or excipients.

In another aspect of the invention there is provided use offormononetin, for the manufacture of a medicament for the treatment orprevention of menopausal symptoms or osteoporosis, or use of daidzein orformononetin for the manufacture of a medicament for the treatment orprevention of osteoporosis. Generally, the isoflavone is provided in theform of a medicament in association with one or more pharmaceuticallyadjuvants, carriers and/or excipients. Daidzein and/or formononetin maybe conveniently blended as a dry powder with other components and formedinto appropriate dosage forms. Such medicaments generally comprise fromabout 5 mg to about 400 mg of isoflavone.

According to a still further aspect of the invention there is providedan agent for the treatment or prevention of menopausal symptoms orosteoporosis, or an agent for the treatment or prevention of menopausalsymptoms which comprises daidzein optionally in association with one ormore pharmaceutically acceptable adjuvants, carriers and/or excipients.

Daidzein and/or formononetin may be administered in the form of adietary product, as mentioned above, for example in a palatable foodcarrier such as a confectionary bar, biscuit, cereal or beverage.

The methods and compositions of the present invention do not include theuse of estrogens, or components such as licorice, cholecalciferol andvitamin E. Estrogen administration has many side effects such as genitalbleeding and hepatic disorders. Licorice has vasoactive activity and mayexacerbate menopause symptoms or osteoporosis. Cholecalciferol andvitamin E are also disadvantageous.

The foregoing description in relation to daidzein, applies to thedaidzein metabolites equol, o-desmethylangolensin (ODMA), dehydroequol,2-dehydro-ODMA, 6-hydroxy-ODMA, dihydrodaidzein and tetra-hydrodaidzein,as well as combinations of the above species. Hence daidzein may bereplaced by one or more of these metabolites. Daidzein or formononetinmay also take the form of aglycones, glycosides, malonyl or acetylderivatives.

This invention will now be described with reference to the followingnon-limiting examples.

Example 1

Peri-menopausal women with symptoms of acute menopausal syndromeincluding at least an average of 3 hot flush episodes per day weretreated with a preparation containing a concentrated amount of daidzein,formononetin, genistein and biochanin prepared according to the methoddescribed in published Australian patent application 40523/93(incorporated herein by reference). The preparation contained 100 mgisoflavones containing biochanin and formononetin (in the ratio of1.8:1). Urine samples were collected from each woman at the start of thetest and then again at the end of the trial and the levels of particularisoflavones in the urine (as a marker of total body isoflavone ratios)then correlated with the degree of reduction in the incidence of hotflushes per day over the course of the study. Daidzein and genisteinwere detected in the urine of all test subjects but the levels werehighly variable, ranging from barely detectable to relatively high.Formononetin and biochanin levels ranged between undetectable andsignificant. Genistein levels showed no correlation with therapeuticresponse; daidzein levels correlated well with therapeutic responseindicating potential therapeutic utility of daidzein and formononetin.

Example 2

Daidzein substantially free of other isoflavones was prepared from soyby the following method. 1 kg of defatted soyflour (readily availablefrom many commercial sources) was added to 10 L of water containing 50 gof glucan hydrolase enzyme (Bio-Feed Beta CT, Novo Nordisk, Denmark). Tothis suspension 5 L of ethyl acetate is then added. This mixture ismixed vigorously using a high pressure pump for 3 hours so that it formsan emulsion. This mixing ensures effective contact between the aqueousphase and the miscelles of ethyl acetate so that the enzymaticallyhydrolysed aglucone forms of the isoflavones move from the aqueous tothe organic solvent phase. The three phases (soyflour, aqueous, ethylacetate) are separated by centrifugation in a swing bucket centrifuge at2000 g for 30 minutes. The upper phase comprising ethyl acetate isaspirated, 200 ml of water added, and then placed into a rotaryevaporator at 75° C. under a weak vacuum. Upon removal of the ethylacetate, the residual aqueous phase containing the isoflavones isextracted once with 500 ml of hexane to remove oils and fats, and thentwice with 500 ml of octanol which selectively removes genistein. Theaqueous phase then was taken to dryness overnight in an oven at 80° C.This material was shown by high pressure liquid chromatographic analysisto comprise 65% isoflavones comprising daidzein (95%) : genistein(5%) :formononetin(0%) : biochanin(0%). This material was mixed with standardcarriers/excipients and tableted to give 500 mg tablets containing 25 mgdaidzein. In this particular example, the daidzein was tableted withequivalent (w/w) amounts of microcrystalline cellulose, calcium hydrogenphosphate, magnesium stearate and anhydrous colloidal silica.

Formononetin substantially free of other isoflavones was prepared fromclover by enzyme/solvent as above. Formononetin was recovered as apurity level greater than 95% by chromatographic analysis or by HPLC.

Example 3

The dried end product of the first part of Example 2 above can be usedto further concentrate genistein or daidzein with/without. 3 kg of thismaterial is mixed with 1000 L of an organic solvent such as acetone,chloroform or octanone, but preferably acetone for reasons of safety andcost. Each of these 3 solvents has been shown by the inventors to havehigh affinity for genistein but not daidzein. The mixture is stirredcontinuously at room temperature for between 1-24 hours but preferably 2hours during which time a large amount (approximately 75%) of thegenistein transfers into the solvent phase. The mixture is allowed tosettle for about 2 hours, the solvent is separated from the residue(Sample 2) and transferred to a still for evaporation. Sample 2 materialpreferably is extracted with acetone a further 1-5 times (preferably 4times). This material typically contains 76% daidzein, 1% genistein,0.5% glycetein, with the remainder comprising residual lipid solublematerial such as short chain fatty acids. On a w/w basis compared withthe other isoflavones, this preparation contains 98% (w/w) daidzein.Daidzein may be purified to 95% (w/w) of total material or more purityby preparative purification regimens such as preparative HPLC. Adaidzein preparation according to this example is tableted withconventional inert excipients according to Example 3 to give a 200 mgtablet containing 50 mg daidzein.

Example 4

A group of 36 post-menopausal women experiencing menopausal symptomswere treated with a composition containing either 15 mg daidzein or 60mg daidzein administered on a daily basis for 3 months. Compared to aplacebo control group there was a significant decrease in the GreeneScore for menopausal symptoms which corresponds totreatment/amelioration of menopausal symptoms (such as hot flushes). Theurinary profile of these subjects demonstrated the therapeuticeffectiveness of daidzein as against other isoflavones. In a similarstudy the same dosage levels of formononetin again gave a significantdecrease in Greene Score for menopausal symptoms as for daidzein.

Example 5

A pharmacokinetic study involving 16 human patients aged between 18 and40 was conducted, to determine the pharmacokinetics of formononetinfollowing oral administration. Each patient was orally administered 9.3mg of formononetin with 200 ml of purified water and maintained a lowisoflavone diet for one week prior to, and during the study. Bloodsamples were taken at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3, 4, 5,6, 8, 10 and 12 and 24 hours post administration, and analysed forformononetin concentration.

An analysis of formononetin concentrations (ng/ml) against timedemonstrated that contrary to previous opinion, unmetabolisedformononetin persists in the blood stream for considerable timefollowing administration (having a half life of about 20 hours).

Example 6

15 post-menopausal women who are experiencing menopausal systems areeach administered 60 mg formononetin daily for three months_(—) Relativeto a control group the treatment group show a significant decrease inGreene Score for menopausal symptoms.

A similar study involving 10 post-menopausal women in a high risk groupfor osteoporosis were also administered 60 mg formononetin daily forthree months. Preliminary results indicate protection againstosteoporosis in the treatment group when measured by bone density andbone turnover markers were measured.

Example 7

The second study (double-blind, placebo-controlled) involved a six monthstudy of the effects of phytoestrogen formononetin on bone resorptionmarkers in twenty post-menopausal women. The aim of the study was toevaluate the efficacy of a defined daily quantity of isoflavone at 25mg, 50 mg or 75 mg on bone resorption makers in post menopausal womenand compare these to normal controls The effects of isoflavones onendometrial thickness, circulatory lipids and coagulation factors werealso evaluated. Subjects were also given supplemental calcium in a doseof 1200 mg per day.

Bone density measurements using a bone densitometer were made at threesites of the forearm at 0.3 and 6 months and showed significantimprovement in bone density. Bone markers for osteocalcin, deoxypyridinoline crosslinks, N-terminal collagen crosslinks, calcium andother markers showed a similar improvement in bone resorption andturnover.

It is to be recognized that the present invention has been described byway of example only, and that various modifications and/or alterationswhich would be obvious to a person skilled in the art, on the basis ofthe teaching herein, can be made thereto without departing from theintended scope or spirit of the invention.

1.-31. (canceled)
 32. A composition for the treatment or reduction ofmenopausal symptoms in a post-menopausal woman, said compositioncomprising an effective amount of formononetin and biochanin A, whereinthe formononetin represents at least about 90% of the isoflavonecontent, and wherein genistein, if present, is in the amount of about 5%w/w or less.
 33. A composition according to claim 32 wherein theformononetin represents at least about 95% of the isoflavone content.34. A composition according to claim 32 wherein genistein, if present,is about 1% or less with regard to isoflavone content.
 35. A compositionaccording to claim 32 wherein the formononetin is purified from extractsof plants of the genus Leguminosae.
 36. A composition according to claim32 further comprising one or more pharmaceutically acceptable adjuvants,carriers and or excipients.
 37. A composition according to claim 32wherein daidzein, if present, is one or more daidzein metabolitesselected from equol, o-desmethylangolensin, dehydroequol,2-dehydro-o-desmethylangolensin, 6-hydroxy-o-desmethylangolensin,dihydrodaidzein and tetra-hydrodaidzein.
 38. A composition according toclaim 37, wherein at least one daidzein metabolite is in the aglycone,glycoside, malonyl or acetyl form.